Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IQ Therapeutics has concluded dosing in a randomized, placebo controlled, double blind, single dose-escalating Phase I clinical trial assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of antibody IQNLF against anthrax.
Subscribe to our email newsletter
IQ Therapeutics said doses up to 7.5 mg/kg have been administered, as per protocol.
IQNLF is a fully human antibody developed using IQ Therapeutics’ proprietary technology – Cloning the Human Response, as part of a dual antibody treatment of inhalation anthrax.
IQNLF is formulated in combination with a second fully human antibody (IQNPA) forming IQ-DAA.
Pre-clinical experiments have indicated high efficacy of IQ-DAA, even in advanced stage of disease.
IQ Therapeutics CEO Roland Lageveen said the outcome of the clinical study will provide more insight in the safety of IQNLF and how well the antibody is accepted by the human body at levels that are projected to be efficacious.
"It represents another important milestone in the development of IQ-DAA, and the initial results reflect the value of IQ’s Cloning the Human Response technology," Lageveen said.